Adrian F. Hernandez, MD

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis(SIGNIFICANT), Bayer Corporation US(MODEST), Boston Scientific(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Merck & Co., Inc.(MODEST), Pfizer(MODEST), AstraZeneca Pharmaceuticals(MODEST), Relypsa(MODEST), Amgen Inc.(MODEST), Biofourmis(MODEST), Sanofi-Aventis(SIGNIFICANT), Cytokinetics(MODEST), Myokardia(MODEST), Eli Lilly and Company(MODEST) RESEARCH/RESEARCH GRANTS: AstraZeneca(SIGNIFICANT), Novartis(SIGNIFICANT), Genentech, Inc(MODEST), Daiichi Sankyo(MODEST), Verily(SIGNIFICANT), Merck & Co., Inc.(MODEST), American Regent(MODEST), Janssen Pharmaceuticals, Inc(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), GlaxoSmithKline(MODEST), Eli Lilly and Company(NONE) OTHER FINANCIAL BENEFIT: CSL Behring (MODEST), Bristol-Myers Squibb Company (MODEST)

View Full Disclosure